Wegovy is a subcutaneous injection, meaning you administer it as a shot just beneath the skin, once a week. It comes as a prefilled, single-use pen that delivers a fixed dose of semaglutide, a synthetic version of a hormone your body already produces. The pen hides the needle and automates most of the process, so the experience feels closer to clicking a button against your skin than to what most people picture when they hear “injection.” But the mechanics of the device are only half the story; what happens after the drug enters your body is where things get interesting.
What the Prefilled Pen Looks Like and How You Use It
Wegovy ships as a prefilled, single-dose pen. You don’t draw medication from a vial, select a dose, or handle a loose needle. The pen comes preloaded with one of several dose strengths, and the needle is concealed inside a cap that only exposes it when pressed against the skin. You choose an injection site on your abdomen, thigh, or upper arm, press the pen flat against the skin, and push a button. A click tells you the injection has started, and you hold the pen in place for several seconds until it finishes. Then you pull it away and dispose of the whole pen.
This “partially automated” pen design has been studied in human-factors trials. In a crossover study of 100 adults experienced with pen injectors, participants achieved a 95% success rate on their first attempt at dose selection and simulated injection with this type of device.1PubMed Central. Comparative Use Human Factors Study of a Manual vs. A Partially Automated Pen Injector for GLP-1 Receptor Agonist Delivery The hidden needle and fixed dose are deliberate design choices. Research on similar prefilled pens in other drug classes has found that concealing the needle and simplifying the steps substantially improves adherence among people with needle anxiety.2Dermatology Times. Higher Risankizumab Adherence with New Injection Device
Why a Shot Instead of a Pill
Semaglutide is a peptide, a small protein-like molecule. When you swallow a peptide, stomach acid and digestive enzymes break it apart before much of it reaches your bloodstream. An oral version of semaglutide does exist (marketed as Rybelsus for type 2 diabetes), but it relies on a special absorption enhancer and still gets only a tiny fraction of the drug into your system. Oral semaglutide has a bioavailability of roughly 0.8%, meaning over 99% of the dose never makes it past your gut. The injectable version, by contrast, delivers essentially the full dose into subcutaneous tissue, where it absorbs slowly and steadily over hours to days.3Current Trends in Medicine and Clinical Research. From Pills to Injections: Comparing the Pharmacokinetics and Clinical Impact of Oral Semaglutide and Injectable GLP-1 Agonists
That difference in absorption matters for consistency. Blood levels of the oral form fluctuate more from person to person and from dose to dose, with variability in the range of 30 to 50%. The injectable form holds variability between about 10 and 20%.3Current Trends in Medicine and Clinical Research. From Pills to Injections: Comparing the Pharmacokinetics and Clinical Impact of Oral Semaglutide and Injectable GLP-1 Agonists For a weight-management drug that people take long term and that depends on steady blood levels, tighter consistency translates to more predictable results. That is the core reason Wegovy was developed as an injection rather than a daily pill.
What Semaglutide Does Once It Enters Your Body
After the drug absorbs from the injection site, semaglutide mimics a gut hormone called GLP-1. Your body naturally releases GLP-1 after meals, and it signals to your brain that you’ve eaten enough. The natural hormone breaks down within minutes. Semaglutide has been chemically modified to resist that breakdown, so a single weekly shot maintains drug levels between doses.
The brain effects are more complex than a simple “feel full” signal. In animal studies, semaglutide has been shown to directly access several brain regions without fully crossing the blood-brain barrier. Instead, it interacts with the brain through areas near the ventricles and the brainstem that are naturally more permeable. Once there, it activates nerve cells in at least ten brain areas involved in appetite, food reward, and energy expenditure.4PubMed Central. Semaglutide lowers body weight in rodents via distributed neural pathways More recent research has mapped specific brainstem-to-hypothalamus circuits that semaglutide recruits, showing that different pathways handle different jobs: one set suppresses appetite for highly palatable food without changing normal baseline eating, while another pathway independently influences fat metabolism and energy expenditure.5bioRxiv. Semaglutide engages distinct brainstem-to-hypothalamus circuits to suppress motivated feeding and regulate ketogenesis and energy expenditure
In practical terms, people on Wegovy tend to report that food just doesn’t occupy their thoughts the way it used to. Cravings for high-calorie foods diminish. That subjective shift reflects the drug’s action on reward and motivation circuits in the brain, not just the appetite center.
The Stomach-Slowing Effect
Semaglutide also slows how quickly food leaves your stomach, an effect called delayed gastric emptying. In a study of women with obesity, semaglutide significantly increased how much food remained in the stomach at every time point measured. Four hours after eating a test meal, participants on semaglutide still had about 37% of the meal in their stomachs, while those on placebo had emptied completely. The time for half the meal to clear the stomach was roughly 171 minutes on semaglutide compared to 118 minutes on placebo.6PubMed. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity
This effect contributes to feeling full longer after meals, which helps with portion control. But it also explains many of the common side effects. Nausea, especially during the first weeks and after dose increases, is largely driven by the stomach holding onto food longer than your body is accustomed to. That is why Wegovy’s dosing schedule starts low and escalates gradually over several months: it gives your stomach time to adjust to the new pace.
What the Injection Feels Like
The needles on prefilled semaglutide pens are short and thin, designed for subcutaneous injection into fatty tissue rather than muscle. Most people describe the sensation as a brief pinch or pressure, sometimes nothing at all. The injection itself takes only a few seconds of hold time.
Injection site reactions are the more common physical complaint. These can include redness, mild swelling, tenderness, or itching at the spot where you injected. Across GLP-1 receptor agonists as a class, injection site reactions have been reported in up to about 20% of users. The reactions are thought to result partly from the protein-based nature of the drug triggering a localized immune response in the skin.7Skin Appendage Disorders. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications For most people, these reactions are mild and resolve on their own within a day or two. Rotating your injection site each week helps reduce the chance of persistent irritation in one area.
How Much Weight People Actually Lose
Wegovy’s approved dose is 2.4 mg once weekly, and the clinical trial data for this dose is extensive. Across four large trials totaling around 5,000 participants who were overweight or had obesity, subcutaneous semaglutide at 2.4 mg produced dose-dependent weight loss, with higher proportions of participants losing 5 to 10% or more of their starting body weight compared to placebo.8PubMed Central. Clinical review of subcutaneous semaglutide for obesity
In a head-to-head trial comparing weekly semaglutide to daily liraglutide (another injectable GLP-1 drug), semaglutide led to an average weight loss of about 16% at 68 weeks versus roughly 6% with liraglutide. More than half the semaglutide group lost at least 15% of their body weight, compared to 12% of the liraglutide group.9JAMA. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial And these results hold up over time. In a two-year trial, participants on semaglutide maintained an average weight loss of about 15% at 104 weeks, along with meaningful reductions in waist circumference and blood pressure.10Nature Medicine. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
A newer trial has tested a higher 7.2 mg dose and found even larger effects: roughly 19% average weight loss, with participants significantly more likely to hit the 20% and 25% weight-loss thresholds compared to the current 2.4 mg dose.11The Lancet Diabetes & Endocrinology. Efficacy and safety of semaglutide 7·2 mg in obesity: the STEP UP trial Whether and when this higher dose reaches the market remains to be seen, but it illustrates that the injectable platform has room to grow.
Storing the Pens Properly
Because semaglutide is a peptide, it’s sensitive to temperature. Unused pens should be refrigerated. Once you start using a pen (for medications that come in multi-dose pens) or if you’re transporting it, it can be kept at room temperature for a limited window, but heat is the enemy. Laboratory studies have shown that semaglutide maintains its molecular structure up to about 60°C, but beyond that temperature, the protein rapidly unfolds and degrades.12PubMed. Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation For practical purposes, that means leaving a pen in a hot car during summer or exposing it to direct sunlight for extended periods can render the medication less effective or useless. If a pen has been exposed to excessive heat, don’t use it.
Compounded Semaglutide and Safety Risks
The popularity of Wegovy has created supply shortages and high demand, which has led some people to seek semaglutide from compounding pharmacies. Compounded semaglutide typically comes in a vial with separate syringes rather than a prefilled pen. This matters more than it might seem. Compounded vials require you to draw up the correct dose yourself, and the margin for error is real. A case series reported to a poison control center documented patients who accidentally administered ten times their intended dose because they confused units of measurement. These errors were possible specifically because vials lack the safety features built into prefilled pens.13PubMed Central. Administration errors of compounded semaglutide reported to a poison control center-Case series
Beyond dosing errors, the quality of compounded products is less tightly regulated than brand-name pharmaceuticals. And the problem extends further than compounding. The World Health Organization has issued warnings about counterfeit versions of semaglutide pens discovered in regulated supply chains in multiple countries. Counterfeit injectables are especially dangerous because the drug goes directly under the skin, bypassing the body’s first-line defenses.14JAMA. WHO Warns of Counterfeit Ozempic in the Global Supply Chain—Here’s What to Know If you’re obtaining semaglutide, verifying the source matters. Brand-name Wegovy pens should come sealed with lot numbers and expiration dates from the manufacturer.
Your Body’s Immune Response to the Drug
Because semaglutide is a modified peptide and not a simple chemical molecule, your immune system can recognize it as foreign and produce antibodies against it. This is called immunogenicity, and it happens with all biologic drugs to some degree. In clinical trials, a small percentage of participants developed anti-drug antibodies. In most cases, these antibodies had no measurable impact on how well the drug worked. However, researchers continue to refine the laboratory methods used to detect these antibodies, improving sensitivity by orders of magnitude in newer assays.15Bioanalysis. Improving sensitivity and drug tolerance of assays for neutralizing anti-drug antibodies to semaglutide and native GLP-1 The clinical significance is still considered low for most patients, but it is an area of ongoing monitoring, especially for people who use the drug for years.
The Push Toward Non-Injectable Alternatives
Not everyone is comfortable with weekly injections, even ones that are as simple as Wegovy’s pen. Needle reluctance remains a genuine barrier to treatment. Drug developers have recognized this, and the next frontier is oral GLP-1 drugs that work well enough for weight management, not just diabetes. Orforglipron, for example, is a once-daily oral GLP-1 receptor agonist currently in late-stage trials for obesity. Unlike oral semaglutide (which is a peptide requiring an absorption enhancer and still has very low bioavailability), orforglipron is a small molecule, meaning it absorbs through the gut more like a conventional pill.16Expert Opinion on Pharmacotherapy. Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning Whether these oral options will match the injectable’s consistency and weight-loss results remains an open question, but for the millions of people who would benefit from treatment but resist needles, they could change the calculus entirely.
The Environmental Side of Disposable Pens
Each Wegovy pen is used once and discarded. Multiply that by millions of prescriptions worldwide, and you get a growing waste problem. A systematic review of injectable drug delivery devices flagged the rise of GLP-1 treatments for home self-injection as a particular concern, noting that these disposable systems cannot be easily dismantled or recycled. The review emphasized the importance of incorporating reusable components and eco-design principles into future devices to reduce long-term environmental impact.17PubMed Central. Sustainability in Injectable Drug Delivery Devices: A Systematic Literature Review of Environmental, Economic, and Public Health Impacts For now, used pens should go into a sharps container and be disposed of through your local medical waste program. They should never go in household recycling or regular trash. As the GLP-1 market continues to expand, pressure on manufacturers to develop more sustainable delivery systems will likely grow.